Myovant’s relugolix wins a pivotal prostate cancer showdown with an old standard — coming down to the wire on approvals
Myovant $MYOV has rounded the final turn in its development race to get relugolix down to the regulatory wire at the FDA. And the biotech joined the virtual crowd at ASCO with the kind of data needed to keep the investor crowd’s attention.
Much of the attention on the drug has been focused on uterine fibroids, where AbbVie just scored a regulatory win for their rival drug Oriahnn (elagolix) as the biotech posted results in prostate cancer at the ASCO meeting.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.